Invesco Ltd. Has $30.04 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Invesco Ltd. lowered its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 32.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 349,208 shares of the company's stock after selling 171,244 shares during the quarter. Invesco Ltd.'s holdings in Novo Nordisk A/S were worth $30,039,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Center for Financial Planning Inc. lifted its position in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Albion Financial Group UT lifted its position in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC boosted its stake in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after buying an additional 243 shares during the period. Hager Investment Management Services LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $46,000. Finally, Halbert Hargrove Global Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth $47,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a report on Tuesday. They set an "underperform" rating on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Trading Down 7.8 %

Novo Nordisk A/S stock traded down $4.89 during midday trading on Friday, hitting $57.99. 32,192,935 shares of the stock were exchanged, compared to its average volume of 5,975,692. Novo Nordisk A/S has a 52 week low of $57.28 and a 52 week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $260.23 billion, a PE ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a fifty day simple moving average of $75.52 and a two-hundred day simple moving average of $91.71.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a $0.7874 dividend. The ex-dividend date of this dividend was Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.